Biliary tract tumors: past, present and future

  • Angela Lamarca
  • Enrique Espinosa
  • Jorge Barriuso
  • Jaime Feliu


Tumors of the biliary tract (gallbladder tumors, cholangiocarcinomas and ampullary carcinomas) are low incidence tumors with poor prognosis. The five-year overall survival is 50% for stage I, 30% stage II, 10% stage III and 0% stage IV. Treatment is based on surgery for potentially resectable tumors. Chemotherapy and chemo-radiotherapy is the treatment of choice when surgery is not amenable, however it has not achieved encouraging results. These patients use to have very few symptoms, which is the reason for the delay in diagnosis and the poor prognosis. They frequently develop biliary obstruction: obstructive jaundice, right upper quadrant pain and weight loss. Ampullary carcinomas are frequently related to steatorrhea due to malabsorption. The most effective chemotherapy drugs used in monotherapy are 5FU (response rate 20%) and gemcitabine (response rate of 13%–60%), so they have been selected for further development in multiple phase II clinical trials to explore their efficacy and safety in combination with other agents. In a phase III clinical trial, combination of gemcitabine and cisplatin has been selected as the schedule of choice. Target therapies are also being developed in this malignancy. The present work reviews the most current knowledge of the pathogenesis, diagnosis and natural history of biliary tract tumors. Further, review of surgery, current adjuvant treatment and therapies for unresectable and advanced disease is provided. The most recent understanding for target therapies and molecular biology is also summarized.

Key words

biliary tract tumors chemotherapy surgery radiotherapy target therapies 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eckel F, Brunner T, Jelic S. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010, 21 Suppl 5: 65–69.CrossRefGoogle Scholar
  2. 2.
    Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th Ed. Springer-Verlag. 2010.Google Scholar
  3. 3.
    Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer, 1992, 70: 1493–1497.Google Scholar
  4. 4.
    Gourgiotis S, Kocher HM, Solaini L, et al. Gallbladder cancer. Am J Surg, 2008, 196: 252–264.PubMedCrossRefGoogle Scholar
  5. 5.
    Gatto M, Alvaro D. Cholangiocarcinoma: risk factors and clinical presentation. Eur Rev Med Pharmacol Sci, 2010, 14: 363–367.PubMedGoogle Scholar
  6. 6.
    Heinrich S, Clavien PA. Ampullary cancer. Curr Opin Gastroenterol, 2010, 26: 280–285.PubMedCrossRefGoogle Scholar
  7. 7.
    Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg, 1992, 215: 31–38.PubMedCrossRefGoogle Scholar
  8. 8.
    Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg, 1999, 134: 526–532.PubMedCrossRefGoogle Scholar
  9. 9.
    Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol, 2010, 28: 3531–3540.PubMedCrossRefGoogle Scholar
  10. 10.
    Gagner M, Rossi RL. Radical operations for carcinoma of the gallbladder: present status in North America. World J Surg, 1991, 15: 344–347.PubMedCrossRefGoogle Scholar
  11. 11.
    Rajagopalan V, Daines WP, Grossbard ML, et al. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Williston Park), 2004, 18: 889–896.Google Scholar
  12. 12.
    Diener MK, Knaebel HP, Heukaufer C, et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreatico-duodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg, 2007, 245: 187–200.PubMedCrossRefGoogle Scholar
  13. 13.
    Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA, 2008, 299: 1019–1026.PubMedCrossRefGoogle Scholar
  14. 14.
    Gold DG, Miller RC, Haddock MG, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys, 2009, 75: 150–155.PubMedCrossRefGoogle Scholar
  15. 15.
    Kresl JJ, Schild SE, Henning GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys, 2002, 52: 167–175.PubMedCrossRefGoogle Scholar
  16. 16.
    Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer, 2002, 95: 1685–1695.PubMedCrossRefGoogle Scholar
  17. 17.
    Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol, 2008, 15: 3147–3156.PubMedCrossRefGoogle Scholar
  18. 18.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg, 1999, 230: 776–782.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer, 2008, 113: 1614–1622.PubMedCrossRefGoogle Scholar
  20. 20.
    Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer, 2008, 113: 2119–2128.PubMedCrossRefGoogle Scholar
  21. 21.
    Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg, 2006, 244: 230–239.PubMedCrossRefGoogle Scholar
  22. 22.
    Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year followup of a prospective phase II study. Gastrointest Endosc, 2004, 60: 68–75.PubMedCrossRefGoogle Scholar
  23. 23.
    Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100: 2426–2430.PubMedCrossRefGoogle Scholar
  24. 24.
    Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology, 2003, 125: 1355–1363.PubMedCrossRefGoogle Scholar
  25. 25.
    Gao F, Bai Y, Ma SR, et al. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci, 2010, 17: 125–131.PubMedCrossRefGoogle Scholar
  26. 26.
    Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford), 2008, 10: 186–189.CrossRefGoogle Scholar
  27. 27.
    Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 1996, 7: 593–600.PubMedCrossRefGoogle Scholar
  28. 28.
    Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs, 2004, 22: 193–198.PubMedCrossRefGoogle Scholar
  29. 29.
    Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol, 1998, 9: 653–656.PubMedCrossRefGoogle Scholar
  30. 30.
    Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer, 1995, 31A(10): 1594–1598.PubMedCrossRefGoogle Scholar
  31. 31.
    Park SH, Park YH, Lee JN, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer, 2006, 106: 361–365.PubMedCrossRefGoogle Scholar
  32. 32.
    Rao S, Cunningham D, Hawkins RE, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer, 2005, 92: 1650–1654.PubMedCrossRefGoogle Scholar
  33. 33.
    Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer, 2008, 98: 309–315.PubMedCrossRefGoogle Scholar
  34. 34.
    Patt YZ, Jones DV Jr, Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol, 1996, 14: 2311–2315.PubMedGoogle Scholar
  35. 35.
    Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol, 2000, 23: 425–428.PubMedCrossRefGoogle Scholar
  36. 36.
    Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res, 2001, 7: 3375–3380.PubMedGoogle Scholar
  37. 37.
    Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol, 2004, 15: 478–483.PubMedCrossRefGoogle Scholar
  38. 38.
    Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol, 2001, 19: 4089–4091.PubMedGoogle Scholar
  39. 39.
    Riechelmann RP, Townsley CA, Chin SN, et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer, 2007, 110: 1307–1312.PubMedCrossRefGoogle Scholar
  40. 40.
    Cereda S, Passoni P, Reni M, et al. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer, 2010, 116: 2208–2214.PubMedGoogle Scholar
  41. 41.
    Bhargava P, Jani CR, Savarese DM, et al. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park), 2003, 17: 23–26.Google Scholar
  42. 42.
    André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol, 2004, 15: 1339–1343.PubMedCrossRefGoogle Scholar
  43. 43.
    Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol, 2010, 28: 4581–4586.PubMedCrossRefGoogle Scholar
  44. 44.
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362: 1273–1281.PubMedCrossRefGoogle Scholar
  45. 45.
    Julka PK, Puri T, Rath GK. A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int, 2006, 5: 110–114.PubMedGoogle Scholar
  46. 46.
    Williams KJ, Picus J, Trinkhaus K, et al. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford), 2010, 12: 418–426.CrossRefGoogle Scholar
  47. 47.
    Bridgewater JA, Palmer D, Cunningham D, et al. Second-line therapy in advanced biliary tract cancer: baseline data from retrospective multicenter series. Ann Oncol, 2012, 23: 224–257.Google Scholar
  48. 48.
    Malka D, Trarbach T, Fartoux L, et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol, 2009, 27: 4520.Google Scholar
  49. 49.
    Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliarytract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol, 2010, 11: 48–54.PubMedCrossRefGoogle Scholar
  50. 50.
    Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol, 2006, 24: 3069–3074.PubMedCrossRefGoogle Scholar
  51. 51.
    Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II consortium study. J Clin Oncol, 2010, 28: 3491–3497.PubMedCrossRefGoogle Scholar
  52. 52.
    Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer, 2010, 10: 631.PubMedCrossRefGoogle Scholar
  53. 53.
    Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol, 2009, 64: 777–783.PubMedCrossRefGoogle Scholar
  54. 54.
    Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer, 2010, 102: 68–72.PubMedCrossRefGoogle Scholar
  55. 55.
    El-Khoueiry AB, Rankin C, Lenz HJ, et al. SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. ASCO Annual Meeting Proceedings Part I. J Clin Oncol, 2007, 25: 4639.Google Scholar
  56. 56.
    Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol, 2011, 29: 2357–2363.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Angela Lamarca
    • 1
  • Enrique Espinosa
    • 1
  • Jorge Barriuso
    • 1
  • Jaime Feliu
    • 1
  1. 1.Medical Oncology DepartmentLa Paz Universitary Hospital, IdiPazMadridSpain

Personalised recommendations